Press Releases Cybin Inc.

Equities

CYBN

CA23256X1006

Market Closed - Nyse Other stock markets 16:00:00 2024-06-18 EDT			5-day change	1st Jan Change
0.272 ^USD	+0.07%		-9.03%	-33.66%

06-11	Cybin Inc. Appoints Atul R. Mahableshwarkar as Senior Vice President, Clinical Development	CI
05-06	Cybin Provides Corporate Provides Update Highlighting Recent Clinical Accomplishments and Key Upcoming Catalysts Across Its Development Pipeline	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Cybin to Participate in the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference	06-19	BU
Cybin Appoints Dr. Atul Mahableshwarkar M.D., as Senior Vice President, Clinical Development	06-11	BU
Cybin to Participate at the Pathways to Access Summit and the Interdisciplinary Conference on Psychedelic Research 2024	05-29	BU
Cybin to Participate in the Alliance Global Partners Healthcare Company Showcase	05-14	BU
Cybin Provides Corporate Update and Highlights Upcoming Clinical Milestones	05-07	AQ
Cybin Provides Corporate Update and Highlights Upcoming Clinical Milestones	05-06	BU
Cybin to Participate at the 27th Annual Milken Institute Global Conference	04-25	BU
Cybin Announces Publication of Research Manuscript in the Journal of Medicinal Chemistry	04-18	BU
Cybin Announces Grant of Additional U.S. Patent in Support of its CYB003 Breakthrough Therapy Program for Major Depressive Disorder	04-16	BU
Cybin to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference	04-10	BU
Cybin : MATERIAL CHANGE REPORT - Form 6-K	03-22	PU
Cybin : AGENCY AGREEMENT - Form 6-K	03-21	PU
Cybin to Present at Public Ventures Discovery Day on March 19th in Dallas	03-18	BU
Cybin Initiates Phase 2 Proof-of-Concept Study of CYB004 in Generalized Anxiety Disorder	03-15	BU
Discovering Promising Tech Stocks: QBTS, GEVI, CYBN, RSCI, CLRO	03-15	AQ
Cybin Announces Positive End-of-Phase 2 Meeting with FDA for CYB003 in Major Depressive Disorder and Phase 3 Program Design	03-14	BU
Cybin Inc. - Announces Oversubscribed Private Placement of U.S. $150 Million	03-14	AQ
Cybin Receives FDA Breakthrough Therapy Designation for its Novel Psychedelic Molecule CYB003 and Announces Positive Four-Month Durability Data in Major Depressive Disorder	03-13	BU
Cybin to Host Conference Call and Webcast to Provide Program Update for CYB003	03-12	BU
Cybin to Present at the TD Cowen 44th Annual Health Care Conference	02-27	BU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Cybin Inc.

Equities

CYBN

CA23256X1006

Press Releases

Filters